Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

SARS-CoV-2 IgG screening of 1,000 antenatal serum samples in the Oxford area, United Kingdom, between 14 April and 15 June 2020, yielded a 5.3% seroprevalence, mirroring contemporaneous regional data. Among the 53 positive samples, 39 showed in vitro neutralisation activity, correlating with IgG titre (Pearson's correlation p<0.0001). While SARS-CoV-2 seroprevalence in pregnancy cohorts could potentially inform population surveillance, clinical correlates of infection and immunity in pregnancy, and antenatal epidemiology evolution over time need further study.

Original publication




Journal article


Euro Surveill

Publication Date





COVID-19, ELISA, IgG, antenatal, antibody, epidemiology, neutralisation, pregnancy, prevalence, serology, Adolescent, Adult, Antibodies, Neutralizing, Antibodies, Viral, Betacoronavirus, COVID-19, Cohort Studies, Coronavirus Infections, England, Enzyme-Linked Immunosorbent Assay, Female, Humans, Immunoglobulin G, Middle Aged, Pandemics, Pneumonia, Viral, Population Surveillance, Pregnancy, Pregnancy Complications, Infectious, Pregnancy Trimester, First, Prenatal Diagnosis, Prevalence, SARS-CoV-2, Seroepidemiologic Studies, Single-Blind Method, Young Adult